We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Galectin-1 in Pancreatic Ductal Adenocarcinoma: Bridging Tumor Biology, Immune Evasion, and Therapeutic Opportunities.
- Authors
Bogut, Ana; Stojanovic, Bojan; Jovanovic, Marina; Dimitrijevic Stojanovic, Milica; Gajovic, Nevena; Stojanovic, Bojana S.; Balovic, Goran; Jovanovic, Milan; Lazovic, Aleksandar; Mirovic, Milos; Jurisevic, Milena; Jovanovic, Ivan; Mladenovic, Violeta
- Abstract
Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the most challenging malignancies to treat, with a complex interplay of molecular pathways contributing to its aggressive nature. Galectin-1 (Gal-1), a member of the galectin family, has emerged as a pivotal player in the PDAC microenvironment, influencing various aspects from tumor growth and angiogenesis to immune modulation. This review provides a comprehensive overview of the multifaceted role of Galectin-1 in PDAC. We delve into its contributions to tumor stroma remodeling, angiogenesis, metabolic reprogramming, and potential implications for therapeutic interventions. The challenges associated with targeting Gal-1 are discussed, given its pleiotropic functions and complexities in different cellular conditions. Additionally, the promising prospects of Gal-1 inhibition, including the utilization of nanotechnology and theranostics, are highlighted. By integrating recent findings and shedding light on the intricacies of Gal-1's involvement in PDAC, this review aims to provide insights that could guide future research and therapeutic strategies.
- Subjects
PANCREATIC duct; BIOLOGY; ADENOCARCINOMA; IMMUNOREGULATION; TUMOR growth; PROGRAMMED cell death 1 receptors; NANOMEDICINE
- Publication
International Journal of Molecular Sciences, 2023, Vol 24, Issue 21, p15500
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms242115500